• Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Resea

  2026-05-21

  Quizartinib (AC220) empowers acute myeloid leukemia (AML) research with unparalleled selectivity for FLT3, enabling robust, reproducible results in both in vitro and in vivo settings. This guide delivers actionable protocols, troubleshooting strategies, and translational insights—backed by the latest evidence on overcoming drug resistance in myeloid malignancies.

• Ceftolozane/Tazobactam: Advances in Combating Resistant Gram

  2026-05-20

  This review analyzes the therapeutic innovation of ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor combination, highlighting its enhanced efficacy against resistant Gram-negative pathogens, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. The paper’s findings inform antibiotic selection and resistance management, and contextualize current research strategies utilizing mechanistically distinct agents like synthetic fluoroquinolone antibiotics.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-05-20

  The reference study demonstrates that Chenodeoxycholic Acid (CDCA), via activation of the nuclear receptor FXR, upregulates KLF11 expression and suppresses the JAK2/STAT3 pathway in models of contrast-induced acute kidney injury (CI-AKI). These findings clarify a novel FXR-KLF11-mediated mechanism for renal protection and support the strategic use of FXR agonists in metabolic and kidney disease research.

• Dasatinib Monohydrate: Precision Workflows in CML and Ph+ AL

  2026-05-19

  Dasatinib Monohydrate (BMS-354825) is redefining kinase pathway interrogation in chronic myeloid leukemia and Philadelphia chromosome-positive models, delivering nanomolar potency even against imatinib-resistant BCR-ABL forms. This article translates advanced research findings into actionable workflows, troubleshooting tips, and protocol refinements for preclinical and translational scientists.

• Deferoxamine Mesylate: Iron-Chelating Agent for Oxidative St

  2026-05-19

  Deferoxamine mesylate is a potent iron-chelating agent that sequesters labile iron and mitigates iron-mediated oxidative damage. It is widely used in research on ferroptosis, hypoxia signaling, and tumor inhibition. Its mechanism and efficacy are supported by robust preclinical and molecular evidence.

• Lopinavir (ABT-378): Precision HIV Protease Inhibition in Re

  2026-05-18

  Lopinavir (ABT-378) delivers unmatched efficacy and resistance resilience in HIV protease inhibition assays, even in serum-rich conditions. This guide translates advanced bench research into actionable protocols and troubleshooting strategies, solidifying Lopinavir's role as the gold standard for next-generation antiviral research.

• Perospirone (SM-9018 Freebase): Mechanisms and Research Uses

  2026-05-18

  Perospirone (SM-9018 freebase) is an atypical antipsychotic with high affinity for 5-HT2A, D2, and 5-HT1A receptors, and a novel inhibitor of vascular Kv1.5 channels. Its dual action underpins its utility in schizophrenia research and cardiovascular models. Key numeric claims in this article are supported by peer-reviewed data and APExBIO product specifications.

• Nascent Cone Precursors Identified as Cell-of-Origin in Reti

  2026-05-17

  This study utilizes single-cell longitudinal analysis of RB1-deficient human retinal organoids to pinpoint ATOH7+ nascent cone precursors as the earliest cell-of-origin for human retinoblastoma. The findings clarify the temporal sequence and cellular mechanisms underlying tumor initiation, providing a crucial foundation for targeted therapeutic strategies.

• Anlotinib Hydrochloride: Multi-Target TKI Workflows in Cance

  2026-05-16

  Anlotinib hydrochloride enables precision inhibition of angiogenic and proliferative signaling, outperforming other multi-target TKIs in both endothelial cell and tumor models. This guide delivers actionable protocol refinements, troubleshooting strategies, and real-world insight from recent literature to empower robust cancer research outcomes.

• N3-kethoxal: Selective Guanine Probe for RNA Structure & Map

  2026-05-15

  N3-kethoxal is a synthetic, membrane-permeable nucleic acid probe that enables site-specific labeling of unpaired guanine bases in RNA and DNA. Its unique azide functional group supports bioorthogonal click chemistry, facilitating advanced structural probing, mapping, and interaction studies in vitro and in vivo.

• Quizartinib (AC220): Precision FLT3 Inhibition and the Biolo

  2026-05-15

  Uncover the molecular precision of Quizartinib (AC220) in FLT3 autophosphorylation inhibition and its implications for acute myeloid leukemia research. This article provides a uniquely deep, evidence-based analysis of resistance mechanisms and practical assay design, going beyond conventional guides.

• Cholecystokinin Octapeptide Ammonium: Translational Insights

  2026-05-14

  Explore the multifaceted roles of Cholecystokinin octapeptide ammonium (CCK-8 ammonium) in neurobehavioral research. This cornerstone article provides new translational perspectives, evidence-based protocols, and practical guidance for advanced assay design.

• PKH26 Red Fluorescent Cell Linker Kit: Technical Workflow Gu

  2026-05-14

  The PKH26 Red Fluorescent Cell Linker Kit offers stable and minimally toxic fluorescent labeling of cell membrane lipids, supporting robust cell tracing and proliferation detection in vitro and in vivo. It should not be applied to intracellular or non-membrane targets, ensuring specificity of results in cell biology research contexts.

• FDA-Approved HIV Protease Inhibitor Lopinavir Blocks MERS-Co

  2026-05-13

  The referenced study systematically screened an FDA-approved drug library and identified Lopinavir (ABT-378) among four compounds that inhibit MERS-CoV replication in cell culture. These findings highlight Lopinavir's cross-pathogen antiviral potential and inform rapid repurposing strategies for emerging viral threats.

• Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis

  2026-05-13

  Z-VDVAD-FMK is a potent, cell-permeable, irreversible caspase-2 inhibitor used in apoptosis assays. It blocks mitochondrial cytochrome c release and DNA fragmentation, offering precise tools for dissecting caspase-mediated cell death pathways. APExBIO’s Z-VDVAD-FMK is widely adopted in cancer and neurodegenerative research.

8125 records 13/542 page Previous Next First page 上5页 1112131415 下5页 Last page